MOTIVATION: The development of better tests to detect cancer in its earliest stages is one of the most sought-after goals in medicine. Especially important are minimally invasive tests that require only blood or urine samples. By profiling oligosaccharides cleaved from glycosylated proteins shed by tumor cells into the blood stream, we hope to determine glycan profiles that will help identify cancer patients using a simple blood test. The data in this article were generated using matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry (MALDI FT-ICR MS). We have developed novel methods for analyzing this type of mass spectrometry data and applied it to eight datasets from three different types of cancer (breast, ovarian and prostate). RESULTS: The techniques we have developed appear to be effective in the analysis of MALDI FT-ICR MS data. We found significant differences between control and cancer groups in all eight datasets, including two structurally related compounds that were found to be significantly different between control and cancer groups in all three types of cancer studied.
MOTIVATION: The development of better tests to detect cancer in its earliest stages is one of the most sought-after goals in medicine. Especially important are minimally invasive tests that require only blood or urine samples. By profiling oligosaccharides cleaved from glycosylated proteins shed by tumor cells into the blood stream, we hope to determine glycan profiles that will help identify cancerpatients using a simple blood test. The data in this article were generated using matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry (MALDI FT-ICR MS). We have developed novel methods for analyzing this type of mass spectrometry data and applied it to eight datasets from three different types of cancer (breast, ovarian and prostate). RESULTS: The techniques we have developed appear to be effective in the analysis of MALDI FT-ICR MS data. We found significant differences between control and cancer groups in all eight datasets, including two structurally related compounds that were found to be significantly different between control and cancer groups in all three types of cancer studied.
Authors: Josep Villanueva; John Philip; Carlos A Chaparro; Yongbiao Li; Ricardo Toledo-Crow; Lin DeNoyer; Martin Fleisher; Richard J Robbins; Paul Tempst Journal: J Proteome Res Date: 2005 Jul-Aug Impact factor: 4.466
Authors: G S Leiserowitz; C Lebrilla; S Miyamoto; H J An; H Duong; C Kirmiz; B Li; H Liu; K S Lam Journal: Int J Gynecol Cancer Date: 2007-07-26 Impact factor: 3.437
Authors: Scott R Kronewitter; Maria Lorna A de Leoz; Kyle S Peacock; Kelly R McBride; Hyun Joo An; Suzanne Miyamoto; Gary S Leiserowitz; Carlito B Lebrilla Journal: J Proteome Res Date: 2010-10-01 Impact factor: 4.466
Authors: Sureyya Ozcan; Donald A Barkauskas; L Renee Ruhaak; Javier Torres; Cara L Cooke; Hyun Joo An; Serenus Hua; Cynthia C Williams; Lauren M Dimapasoc; Jae Han Kim; Margarita Camorlinga-Ponce; David Rocke; Carlito B Lebrilla; Jay V Solnick Journal: Cancer Prev Res (Phila) Date: 2013-12-10
Authors: Zhenxin Lin; Haidi Yin; Andy Lo; Mack T Ruffin; Michelle A Anderson; Diane M Simeone; David M Lubman Journal: Electrophoresis Date: 2013-12-27 Impact factor: 3.535
Authors: Penelope M Drake; Wonryeon Cho; Bensheng Li; Akraporn Prakobphol; Eric Johansen; N Leigh Anderson; Fred E Regnier; Bradford W Gibson; Susan J Fisher Journal: Clin Chem Date: 2009-12-03 Impact factor: 8.327
Authors: Scott R Kronewitter; Maria Lorna A De Leoz; John S Strum; Hyun Joo An; Lauren M Dimapasoc; Andrés Guerrero; Suzanne Miyamoto; Carlito B Lebrilla; Gary S Leiserowitz Journal: Proteomics Date: 2012-08 Impact factor: 3.984